Immune checkpoint inhibitors such as anti-PD-L1 and anti-CTLA-4 antibodies are already approved for clinical use in various cancer types, including melanoma and renal cell carcinoma. This evidence concerns the gene CD274 and hereditary clear cell renal cell carcinoma.